Cholesterol reduction yields clinical benefit: Impact of statin trials

Circulation

Volumn 97, Issue 10, 1998, Pages 946-952

  Gould, A Lawrence ^a   Rossouw, Jacques E ^b   Santanello, Nancy C ^a   Heyse, Joseph F ^a   Furberg, Curt D ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Meta analysis; Mortality

Indexed keywords

CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DEXTROTHYROXINE; ESTROGEN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; DIET THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0032539940     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.10.946     Document Type: Article

References (44)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;20:1301-1307.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Sacks FM, Pfeffer MD, Move LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;334:1001-1009.
4. Furberg CD, Adams JP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
5. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer WWV, Mahrer PR. Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:69-976.
6. Waters D, Higgison L, Gladstone P, Kimball B, Le May M, Bocuzzi SJ, Lesperance J. Effects of monotherapy with an HMB-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian coronary atherosclerosis intervention trial (CCAIT). Circulation. 1994;89:959-968.
7. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
8. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92:2419-2425.
9. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.
10. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ. 1971;4:775-784.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
13. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40: 1069-1103.
14. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;2:600-604.
15. Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992;340:1405-1406.
16. Dorr AE, Gunderson K, Schneider JC, Spencer TW, Martin WB. Colcstipol hydrochloride in hypercholesterolemic patients: effect on serum cholesterol and mortality. J Chronic Dis. 1978;31:5-14.
17. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu UA. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation. 1969;40(suppl II):II-1-II-63.
18. Wilhelmsen L, Berglund G. Elmfeldt D, Tibblin G. Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werko L. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986;7:279-288.
19. Multiple Risk factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA. 1982;248:1465-1477.
20. Miettinen TA, Huttunen JK, Naukkarinen V. Multifactorial primary prevention of cardiovascular diseases in middle-aged men: risk factor changes, incidence, and mortality. JAMA. 1985;254:2097-2102.
21. Hjerman I, Byre KV, Holme I, Leren P. Effect of diet and smoking on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial of healthy men. Lancet. 1981;2:1303-1310.
22. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Kamegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissen JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, for the POSCH group. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH): effect of partial ilial bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
23. Carlson LA, Kosenhamer G. Reduction of mortality in the Stockholm Ischemie Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
24. Coronary Drug Project Research Group. The findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA. 1972;220:996-1008.
25. Schoch HK. The US Veterans Administration cardiology drug-lipid study: an interim report. In: Holmes WL, Carlson LA, Paoletti R, eds. Drugs Affecting Lipid Metabolism. New York, NY: Plenum Press; 1969:405-420.
26. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study frame population. Ann Intern Med. 1993;25:41-45.
27. Coronary Drug Project Research Group. The Coronary Drug Project: clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
28. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coil Cordial. 1986;8:1245-1255.
29. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atkerosclerosis. 1972;15:177-183.
30. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease: five year study by a group of physicians of the Newcastle Upon Tyne region. BMJ. 1971;4:767-775.
31. Oliver MF, Boyd GS. Influence of reduction of serum lipids on prognosis of coronary heart disease: a five year study using oestrogen. Lancet. 1961; 2:499-505.
32. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2:757-761.
33. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist CRB. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol. 1978;109:317-330.
34. Research Committee. Low-fat diet in myocardial infarction: a controlled trial. Lancet. 1965;2:501-504.
35. Rose GA, Thompson WB, Williams RT. Corn oil in treatment of ischemie heart disease. BMJ. 1965;1:1531-1533.
36. Research Committee to the Medical Research Council. Controlled trial of soyabean oil in myocardial infarction. Lancet. 1968;2:693-700.
37. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand. 1966; 466(suppl):l-92.
38. Brown G, Alben JJ, Fisher LD, Schaefer SM, Lin J, Kaplan C, Zhao X, Besson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
39. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LR, Mann JL, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
40. Brensike JF, Levy RI, Kelsy SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarity KJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
41. Blankenhorn DH, Nessim SA, Johnson RI, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
42. Sahni R, Maniet AR, Voci G, Banka VS. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
43. Fail PS, Sahni RS, Maniett AR, Voci G, Banka VS. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty, Clin Res. 1992;40:400A. Abstract.
44. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.